Purification of soluble beta-glucan with immune-enhancing activity from the cell wall of yeast [Saccharomyces cerevisiae]
β-Glucan, one of the major cell wall components of Saccharomyces cerevisiae, has been found to enhance immune functions, especially by activating macrophages. However, a major obstacle to the clinical application of β-(1→3)-glucan is its low solubility in aqueous media. In this study, soluble β-gluc...
Gespeichert in:
Veröffentlicht in: | Bioscience, biotechnology, and biochemistry biotechnology, and biochemistry, 2001-04, Vol.65 (4), p.837-841 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | β-Glucan, one of the major cell wall components of Saccharomyces cerevisiae, has been found to enhance immune functions, especially by activating macrophages. However, a major obstacle to the clinical application of β-(1→3)-glucan is its low solubility in aqueous media. In this study, soluble β-glucan, free of mannoprotein, was prepared, and its effects on TNF-α secretion and phagocytosis by macrophages were evaluated. β-Glucan was first rendered soluble from the yeast cell wall by alkaline extraction (glucan-p1). The extract contained 2.8% of protein which was subsequently removed by successive DEAE-cellulose and ConA chromatography. β-Glucan thus prepared was completely free of mannoprotein and was soluble at neutral pH (glucan-p3). The effects of β-glucan on phagocytosis and TNF-α release activity were investigated. While glucan-p1 moderately induced TNF-α secretion at 200 μg/ml (550 pg of TNF-α/5×10
5
cells), glucan-p3 markedly stimulated macrophages at 200 μg/ml (2,860 pg of TNF-α/5×10
5
cells). Furthermore, glucan-p3 stimulated phagocytosis about 20% more than glucan-p1 did. In conclusion, we purified watersoluble β-glucan which was completely devoid of mannoprotein and effectively stimulated the macrophage function, enabling it to be used as an intravenous injection for sepsis. |
---|---|
ISSN: | 0916-8451 1347-6947 |
DOI: | 10.1271/bbb.65.837 |